[Role of PKC in the pathogenesis of diabetic vascular complications].
作者信息
Inoguchi Toyoshi, Umeda Fumio
机构信息
Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University.
出版信息
Nihon Rinsho. 2002 Oct;60 Suppl 10:67-72.
PMID:12430209
Abstract
摘要
相似文献
1
[Role of PKC in the pathogenesis of diabetic vascular complications].
Nihon Rinsho. 2002 Oct;60 Suppl 10:67-72.
2
Molecule of the month. Ruboxistaurin mesilate hydrate.
Drug News Perspect. 2003 Dec;16(10):691.
3
Ruboxistaurin.
Drugs Today (Barc). 2006 Sep;42(9):577-85. doi: 10.1358/dot.2006.42.9.996566.
4
Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.鲁伯斯塔林，一种蛋白激酶Cβ抑制剂，作为糖尿病微血管并发症的新兴治疗方法。
Ann Pharmacother. 2005 Oct;39(10):1693-9. doi: 10.1345/aph.1E572. Epub 2005 Sep 13.
5
Ruboxistaurin for diabetic retinopathy.鲁比前列酮用于治疗糖尿病性视网膜病变。
Ophthalmology. 2006 Dec;113(12):2135-6. doi: 10.1016/j.ophtha.2006.09.003.
6
[Role of advanced glycation end products and activation of PKC in diabetic retinopathy].[晚期糖基化终末产物及蛋白激酶C激活在糖尿病视网膜病变中的作用]
Nihon Rinsho. 2005 Jun;63 Suppl 6:188-93.
7
Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.蛋白激酶Cβ抑制剂：糖尿病肾病及血管并发症的新治疗靶点。
Fundam Clin Pharmacol. 2008 Jun;22(3):231-40. doi: 10.1111/j.1472-8206.2008.00583.x.
8
[New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].[糖尿病视网膜病变治疗的新前景。现状与药理学进展]
MMW Fortschr Med. 2003 Apr 3;145(14):37-8.
9
PKC inhibition and diabetic microvascular complications.蛋白激酶C抑制与糖尿病微血管并发症
Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):573-86. doi: 10.1016/j.beem.2007.09.007.
10
[Protein kinase C beta-Inhibitor ruboxistaurin].[蛋白激酶Cβ抑制剂鲁比前列酮]
Med Monatsschr Pharm. 2005 Aug;28(8):292-3.
Zotero 插件